Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

FDA Approves MSD’s Keytruda® Combo for Third Endometrial Carcinoma Indication

Jun 17, 2024

On 17 June 2024, Merck (known as MSD outside the US and Canada) announced that the US FDA has approved its anti-PD-1 therapy, Keytruda® (pembrolizumab) in combination with carboplatin and paclitaxel for primary advanced or recurrent endometrial carcinoma. 

This is the first FDA-approved anti-PD-1 therapy for this indication and the third FDA-approved indication for Keytruda® in endometrial carcinoma.  Keytruda received FDA-approval in March 2022 as a single agent for advanced endometrial carcinoma that is MSI-H or dMMR, and in combination with lenvatinib for such cancer that is not MSI-H or dMMR.